Year
2023
-
Aldeyra’s reproxalap for dry eye disease accepted by FDA
-
Roche’s Crovalimab Trial Reaches Endpoints in Patients With PNH
-
Sage and Biogen’s Depression Drug Candidate Gets Priority Review
-
Rocket Pharmaceuticals Gets RMAT Designation for Danon Disease Gene Therapy
-
Janssen’s Nipocalimab Shines in HDFN Trial
-
EMA Clarifies Its Policy on Biosimilar Interchangeability
-
Mesoblast Cell Therapy Gets RMAT Designation for Chronic Low Back Pain
-
FDA Expands Approval for Takeda’s Takhzyro
-
FDA Approves Regeneron’s Eylea for Infants With ROP
-
FDA Extends Ibuprofen Suspension Guidance